Question · asked by 1 review
Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs placebo: Adverse events
- Population
- Adults with cancer receiving treatment
- Intervention
- Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous
- Comparison
- placebo
- Outcome
- Adverse events
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs Placebo Adverse events · Adults with cancer receiving treatment Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and… (2017) · Cochrane All outcomes | Adverse events attributed to KGF were typically oral-related or skin-related; mostly mild to moderate with very few serious events; reporting poor and inconsistent, not appropriate to meta-analyse (SoF comments cell,… | 16 studies | GRADE not reported |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes | 2017-05 | Not listed | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.